Last updated on September 2017

"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) "


Brief description of study

"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) "

Detailed Study Description

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab. Purpose of the study is also to evaluate the safety and tolerability of copanlisib. Approximately 567 patients will be randomly assigned in in blinded treatment arms copanlisib plus rituximab or placebo plus rituximab.

Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo dosing will be administered on the same days as copanlisib.

Rituximab dose is administered weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9. The maximum administration of rituximab is 8 times.

Copanlisib or placebo treatment will be continued until disease progression, unacceptable toxicity, or until another criterion is met for withdrawal from the study treatment.

Following the end of treatment visit, patients will enter either the Safety follow-up or the Active follow-up period.

The efficacy is measured by duration of progression-free survival (time between randomization and onset of a further progression of disease, or death from any cause). Progression of disease will be determined by radiologic tumor assessments to be performed at screening, as well as during the active follow up period tumor assessments every 8 weeks during Year 1, every 12 weeks during Year 2, and every 24 weeks during Year 3.

Blood samples will be collected for safety analysis and pharmacokinetic analysis. Archival tumor tissue and blood samples will be collected for biomarker analysis and for central pathology review, fresh biopsy tissue and bone marrow will be collected but not mandatory.

For Study Locations, Click Here

Clinical Study Identifier: TX153140

Contact Investigators or Research Sites near you

Start Over

Research Center

Research Center
Additional Locations, XX Argentina
6.84miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.